Vitamin D and airway obstruction

Efficacy of vitamin D in the improvement of pulmonary function tests in patients with chronic obstructive pulmonary disease

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201103154724N2

Enrollment

Registered

2011-07-24

Start date

2011-06-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: COPD patients. Condition 2: COPD. Condition 3: COPD. Condition 4: COPD. Condition 5: COPD. Condition 6: COPD. Condition 7: COPD. Condition 8: COPD. Bronchitis, not specified as acute or chronic Simple and mucopurulent chronic bronchitis Unspecified chronic bronchitis Emphysema Other chronic obstructive pulmonary disease Asthma Status asthmaticus Bronchiectasis

Interventions

Intervention 1: 30 patients will take 50.000 IU oral vitamin D3 weekly in addition to their usual treatment regimen of vitamin D will be adjusted over the study period to maintain serum 25-hydro

Treatment - Drugs

Placebo

30 patients will take 50.000 IU oral vitamin D3 weekly in addition to their usual treatment regimen of vitamin D will be adjusted over the study period to maintain serum 25-hydroxyvitamin D leve

The control group receives placebo in addition to their usual drugs

Eligibility

Sex/Gender

All

Age

35 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria : All eligible patients with chronic obstructive pulmonary diseases(COPD) will be included to study. Exclusion criteria :Patients with chronic pulmonary infections ;restrictive airway diseases;cor pulmonale;congestive heart failure;pulmonary emboli neoplasia;occupational lung disease and pregnant women will be excluded .

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Mean differences in FEV1,FVC,FEV1/FVC,from baseline after 3 and six months. Timepoint: 3 months and 6 months interval. Method of measurement: Pulmonary function test (PFT).	—

Secondary

Measure	Time frame
Proportions of patients responded to the treatment (defined as 20% improvement in FEV1 absolute value in ml compared with baseline values) in treatment group compared with placebo group. Timepoint: After 3 months and 6 months of treatment. Method of measurement: PFT.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBehzad Heidari MD

Babol University of Medical Sciences

heidaribeh@yahoo.com+98 11 1223 8284

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026